(CercleFinance.com) – The Janssen Pharmaceutical Companies of Johnson & Johnson presented the final analysis of the Phase 2 GRIFFIN study for the experimental DARZALEX (daratumumab)-based quadruplet regimen in patients with multiple myeloma newly diagnosed and eligible for a transplant.
The data was presented at the plenary session of the International Myeloma Society (IMS) annual meeting.
‘The final analysis from the GRIFFIN trial highlights the potential benefit of adding daratumumab to RVR for the treatment of newly diagnosed, transplant-eligible patients,’ said Douglas W. Sborov, MD, MS , director of the multiple myeloma program at the Huntsman Cancer Institute at the University of Utah and investigator of the GRIFFIN study.
“We are constantly investigating the role of new regimens and combinations in improving outcomes for our patients and GRIFFIN is another important step in this research. ‘
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
